Topical tacrolimus and malignancy risk: Should the theory be put to rest?

For 2 decades, topical calcineurin inhibitors (TCIs) have been United States Food and Drug Administration-approved mainstays of therapy for atopic dermatitis (AD). Every seasoned dermatologist can discuss their off-label experience using TCIs with good evidence for their efficacy—vitiligo, psoriasis of the face, genitals, and intertriginous regions; seborrheic dermatitis, contact dermatitis, oral lichen planus, lichen sclerosus, morphea, and...